Day: June 18, 2022

Press Release Agreement with BARDA on ZENEO® Midazolam  BARDA places a firm order of $60m to CROSSJECT for initial procurement of ZENEO® Midazolam into the U.S. Strategic National Stockpile1 as soon as FDA Authorization is obtainedBARDA also financially supports the U.S. late-stage development and regulatory activities necessary to obtain FDA approval of ZENEO® Midazolam 10mg and a new pediatric dose ZENEO® Midazolam auto injectorBARDA has the option to procure additional ZENEO® Midazolam auto injectors from CROSSJECTDijon, June 18th 2022   CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drug / device combinations for use in emergency situations, is announcing an agreement with BARDA on ZENEO® Midazolam. Patrick Alexandre, Crossject CEO, said:...

VANCOUVER, British Columbia, June 17, 2022 (GLOBE NEWSWIRE) — Western Resources Corp. (TSX: WRX) (the “Company”) is pleased to announce that its Regina-based subsidiary Western Potash Corp. (“Western”) completed a Collaborative Project Planning Session with its key contractors and staff to officially kick off the restart of the Milestone Project (“Project”) in order to complete the process facilities and solution mining development. Key Project representatives participated in a workshop style planning session in Regina to review and gain alignment on key aspects of the project timeline and readiness for start-up, leading into the full ramp up of operations which is expected to happen in mid 2023. The kick off planning session was attended by Western executives and staff and more than 30 people from several different key organizations,...

XIAMEN, China, June 17, 2022 (GLOBE NEWSWIRE) — Blue Hat Interactive Entertainment Technology (“BHAT” or the “Company”) (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games, toys and educational materials in China, today announced that it intends to offer in an underwritten public offering its ordinary shares and pre-funded warrants to purchase ordinary shares. The pre-funded warrants shall be offered at the same price per share as the ordinary shares, less the $0.01 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which include, but are not limited to, advancing and diversifying the company’s product portfolio, and general and administrative...